Tezepelumab reduced exacerbations and reduced type 2 inflammatory biomarkers in patients with and those without NP, supporting its efficacy in a broad population of patients with severe asthma.
No takes yet. Share an insight, caveat, or question.
Emson et al. (2021) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: